Trial Search Results

Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy

Several studies have documented that transplantation of bone marrow-derived cells (BMC) following acute myocardial infarction is associated with a reduction in infarct scar size and improvements in left ventricular function and perfusion. The available evidence in humans suggests that BMC transplantation is associated with improvements in physiologic and anatomic parameters in both acute myocardial infarction and chronic ischemic heart disease, above and beyond the conventional therapy. In particular, intracoronary application of BMC is proved to be safe and was associated with significant improvement in the left ventricular ejection fraction (LVEF) in patients with chronic heart failure.

In contrast to ischemic heart failure, the data on effects of BMC transplantation in patients with dilated cardiomyopathy are limited to pre-clinical studies. In a rat model of dilated cardiomyopathy, intramyocardial delivery of pluripotent mesenchymal cells improved LVEF, possibly through induction of myogenesis and angiogenesis, as well as by inhibition of myocardial fibrosis, suggesting that the beneficial effects of stem cell transplantation in dilated cardiomyopathy may primarily be related to their ability to supply large amounts of angiogenic, antiapoptotic, and mitogenic factors. Similarly, transplantation of cocultured mesenchymal stem cells and skeletal myoblasts was shown to improve LVEF in a murine model of Chagas disease.

Study Aim:

To define the clinical effects of BMC transplantation in dilated cardiomyopathy in a pilot clinical study investigating the effects of intracoronary CD34+ cell transplantation on functional, structural, neurohormonal, and electrophysiologic parameters in patients with end-stage dilated cardiomyopathy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

University Medical Centre Ljubljana

Collaborator: Blood Transfusion Centre of Slovenia

Stanford Investigator(s):


  • Biological: CD34+ autologous stem cell transplantation
  • Drug: Bone Marrow Stimulation
  • Biological: SC therapy


Phase 2


Inclusion Criteria:

   - Normal coronary angiogram

   - Left ventricular ejection fraction < 40%

   - NYHA III or IV heart failure symptoms

   - Bone marrow reactivity (G-CSF test)

   - Presence of viable myocardium

Exclusion Criteria:

   - Hematologic malignancy

   - Multiorgan failure

Ages Eligible for Study

18 Years - 80 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting